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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by
selective loss of motor neurons, muscle atrophy and paralysis. Mutations in the human
VAMP-associated protein B (hVAPB) cause a heterogeneous group of motor neuron dis-
eases including ALS8. Despite extensive research, the molecular mechanisms underlying
ALS pathogenesis remain largely unknown. Genetic screens for key interactors of hVAPB
activity in the intact nervous system, however, represent a fundamental approach towards
understanding the in vivo function of hVAPB and its role in ALS pathogenesis. Targeted ex-
pression of the disease-causing allele leads to neurodegeneration and progressive decline
in motor performance when expressed in the adult Drosophila, eye or in its entire nervous
system, respectively. By using these two phenotypic readouts, we carried out a systematic
survey of the Drosophila genome to identify modifiers of hVAPB-induced neurotoxicity.
Modifiers cluster in a diverse array of biological functions including processes and genes
that have been previously linked to hVAPB function, such as proteolysis and vesicular traf-
ficking. In addition to established mechanisms, the screen identified endocytic trafficking
and genes controlling proliferation and apoptosis as potent modifiers of ALS8-mediated de-
fects. Surprisingly, the list of modifiers was mostly enriched for proteins linked to lipid droplet
biogenesis and dynamics. Computational analysis reveals that most modifiers can be linked
into a complex network of interacting genes, and that the human genes homologous to the
Drosophilamodifiers can be assembled into an interacting network largely overlapping with
that in flies. Identity markers of the endocytic process were also found to abnormally accu-
mulate in ALS patients, further supporting the relevance of the fly data for human biology.
Collectively, these results not only lead to a better understanding of hVAPB function but
also point to potentially relevant targets for therapeutic intervention.
PLOS Genetics | DOI:10.1371/journal.pgen.1005107 March 31, 2015 1 / 32
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Author Summary
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease causing loss of motor
neurons and consequently a progressive deterioration of motor functions. ALS is uniform-
ly fatal with death occurring 5 years after onset of symptoms. There is currently no effec-
tive treatment for ALS. Several mutations in a gene called hVAPB have shown that this
gene is causative of a type of ALS known as ALS8. In this study we sought to identify genes
and cellular processes that are involved in the toxicity conferred by the defective ALS8 al-
lele. By using the power of Drosophila genetics, we performed a large scale genomic screen
and identified a number of genes that can affect hVAPB-mediated toxicity. These modifi-
ers cluster into functional pathways known to be involved in ALS as well as novel ones.
The relevance of these modifiers and mechanisms for the human disease was confirmed
by showing that the human homologues of the fly modifiers can be organized into a net-
work that closely resembles that of the Drosophila genes. Identifying cellular processes and
proteins that modulate hVAPB pathological activity can facilitate the discovery of an effec-
tive treatment for ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of upper and lower
motor neurons leading to a progressive deterioration of motor function and ultimately death,
due to respiratory failure. Both environmental and genetic factors have been shown to contrib-
ute to ALS susceptibility. Approximately 10% of patients with ALS have a family history while
the majority of ALS cases are classified as sporadic [1]. In rare inherited familial forms of ALS,
specific mutations in causative genes have been identified and this has significantly advanced
the field [2]. However, the mechanisms by which these mutations cause motor neuron dysfunc-
tion and death remain unknown.
Several mutations in the human VAMP-associated protein B (hVAPB) have been identified
as being causative of a type of ALS known as ALS8 [3–5]. hVAPB is a member of a highly con-
served protein family involved in a variety of functions including maintenance of endoplasmic
reticulum (ER) morphology, vesicular trafficking and intracellular lipid transport [6]. In C.ele-
gans, the N-terminal domain of the protein is cleaved, secreted and functions as an extracellu-
lar ligand for Ephrin receptors [7]. Secreted fragments also bind to the leukocyte antigen-
related (LAR) and roundabout (Robo) family receptors situated on the muscle cell surface to
control actin organization and mitochondrial morphology and function [8]. Drosophila Vap-
33-1, (hereafter referred as DVAP) controls synaptic remodeling and composition of post-syn-
aptic glutamate receptors [9,10].
The DVAP protein shows only 22% identity with its human orthologue hVAPB but the two
proteins share a common structural organization including a transmembrane domain, a
coiled-coil domain and a N-terminal region, which has a high degree of similarity to the C.ele-
gansmajor sperm proteins (MSP domain). More importantly, expression of hVAPB in flies
can rescue the mutant phenotype associated with DVAP loss-of-function mutations, indicating
that DVAP and hVAPB are functionally interchangeable [10]. DVAP also shows conservation
of residues linked to ALS8 in humans (human P56 is equivalent to fly P58, human T46 is
equivalent to fly T48 and human V260 is equivalent to fly V264) and in Drosophila, expression
of transgenic alleles carrying pathogenic mutations reproduces major hallmarks of the human
disease, including aggregate formation, chaperon up-regulation and locomotion defects
[4,10,11]. A number of studies have implicated the disease-linked alleles in abnormal unfolded
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protein response (UPR) and in the disruption of both the anterograde axonal transport of mi-
tochondria [12] and calcium homeostasis [13]. Moreover, the P56S disease-linked mutation is
a loss-of-function allele through a dominant negative mechanism as it antagonizes the endoge-
nous protein function by recruiting hVAPB into cytoplasmic aggregates [14–16]. Consistent
with this disease mechanism, hVAPB levels are decreased in a number of sporadic cases as well
as in TDP-43 (transactive response DNA-binding protein 43) and in SOD1 (superoxide dis-
mutase 1) models for ALS [17–19]. The ALS causative gene fused in sarcoma (FUS) has been
shown to bind VAPB mRNA and TDP-43 is associated with VAPB-positive aggregates in a
transgenic mouse model expressing the P56S pathogenic allele [20–22]. Taken together, these
data underline the importance of VAPB in ALS pathogenesis and explain why, in recent years,
much effort has been devoted to generate models of ALS8 in a number of experimental organ-
isms including Drosophila [2]. Despite this, the molecular mechanisms and the cellular pro-
cesses underlying ALS8 pathogenesis remain elusive.
Over the last few years, genome-wide genetic screens in yeast have proven to be extremely
powerful in identifying novel genetic risk factors for ALS [23–25] and investigating fundamen-
tal pathogenic mechanisms associated with the ALS disease proteins TDP-43 and FUS [26–29].
These studies have led to the identification of important genetic modifiers of FUS and TDP-43
toxicity, including RNA binding proteins and proteins involved in RNA metabolism, ribosome
biogenesis and cellular stress responses.
To gain insight into fundamental pathogenic aspects of hVAPB-mediated ALS, we adopted
a similar approach and by exploiting the power of Drosophila genetics, we conducted a genetic
screen for modifiers of DVAP-P58S-dependent phenotypes.
From the identified modifiers, a computational network of highly interconnected genes was
assembled that encompasses a wide range of functional categories associated with DVAP-P58S
toxicity. The Drosophila data were evaluated for their relevance to human biology by mapping
the Drosophila genes to their human homologs and showing that the human genes could be in-
tegrated into a network of interacting genes largely overlapping with the Drosophila one. Some
modifiers clustered within cellular processes that were already known to affect hVAPB protein
functions such as proteolysis, intercellular signaling pathways mediated by Robo receptors and
phosphoinositide metabolism [4,8,15]. However, we also identified a number of genes and pro-
cesses that have not been previously associated with hVAPB function. Modifiers included
genes involved in lipid droplet (LD) biogenesis and dynamics as well as endocytosis. We fur-
ther confirmed the role of endocytosis in ALS pathogenesis by showing that the RAB5 GTPase,
an early endosomal marker, is altered in post-mortem tissues of ALS patients. Importantly, a
considerable number of DVAP-P58S modifiers are members of the Ras and Hippo (Hpo) sig-
nal transduction pathways, which control cell proliferation and apoptosis. Our data point to a
mechanistic link between Ras and Hpo signaling on one hand and DVAP-P58S-mediated
ALS8 phenotypes on the other. These results identify genes and cellular processes that widen
our understanding of VAP protein function and provide novel therapeutic targets for ALS and
perhaps other closely related neurodegenerative diseases such as fronto-temporal dementia.
Results
A large-scale screen in Drosophila identifies modifiers of the
DVAP-P58S-induced eye phenotype
To identify genes that influence DVAP-P58S-mediated pathogenesis, we undertook a genetic
modifier screen and looked for genes that upon overexpression suppress or enhance the
DVAP-P58S neurodegenerative phenotype in the eye.
A Network of Functional Interactions in ALS8
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Flies, in which the expression of the DVAP-P58S transgene under the control of the yeast
upstream activating sequence (UAS) was induced by the eyeless-GAL4 (ey-GAL4) driver [30],
exhibit a robust eye phenotype characterized by decreased size, fused ommatidia, missing and
occasionally supernumerary, bristles [15]. A transgenic strain (DVAP-P58S11) was identified,
whose targeted expression in the eye displays a reduction in eye size to about 30% of the wild-
type value making this intermediate phenotype particularly suitable for an enhancer/suppres-
sor screen. This eye phenotype was observed when flies expressing one copy of the DVAP-P58S
transgene (ey,DVAP-P58S), were raised at 30°C to maximize the expression of the transgene
(S1F, G, H Fig). A similar phenotype was also associated with the expression of a double copy
of the same transgene in the eyes of flies (ey,DVAP-P58S/DVAP-P58S) raised at 25°C (S1A, C,
H Fig). At 28°C flies expressing one DVAP-P58S copy exhibited a phenotype that was less se-
vere than that associated with flies of the same genotype raised at 30°C (S1A, C, H Fig). Howev-
er, at 28°C and at 30°C flies carrying a double copy of DVAP-P58S failed to hatch possibly due
to a strong ectopic expression of the transgene outside the eye. Control flies raised at any of
these temperatures did not show any visible eye phenotype (S1A, D, F, H Fig). Taken together,
these data clearly indicate that the reduction in eye size results from DVAP-P58S expression, it
is sensitive to its dosage and it is not affected by the increase in the temperature (S1 Fig). Addi-
tionally, we tested whether other disease features, such as the accumulation of aggregates, were
dependent on the dosage of the pathogenic transgene (S1I, J, K, L, M Fig). Stainings of larval
eye imaginal discs with an anti-DVAP antibody showed a similar accumulation of aggregates
positive to DVAP-immuno-reactivity in both ey,DVAP-P58S flies raised at 30°C and in ey,
DVAP-P58S/DVAP-P58S flies raised at 25°C (S1M, K Fig). A similar accumulation of aggre-
gates was observed in eye imaginal discs of ey,DVAP-P58S flies raised at 28°C (S1L Fig) and
only a few, sporadic aggregates were present in flies of the same genotype raised at 25°C, which
exhibit only a small reduction in eye size (S1J, B Fig). Thus, these data show that the extent of
inclusion accumulation strictly correlates with the expression levels of the pathogenic trans-
gene and with the severity of the eye phenotype.
For simplicity, we decided to use as tester line for the screen, flies carrying a single copy of
the DVAP-P58S transgene raised at 30°C.
A line is considered to be a suppressor if it ameliorates the DVAP-P58S phenotype making
the DVAP-P58S eye size becoming closer to that of the wild-type. By contrast, a line is an en-
hancer if it induces a decrease in the eye size of the ey-Gal4,DVAP-P58S tester line. We previ-
ously showed that the reduction in size is due to DVAP-P58S-mediated perturbations in cell
survival as coexpression of the Drosophila inhibitor of apoptosis 1 (DIAP1) transgene substan-
tially rescues the small eye phenotype, with adult flies displaying nearly normal eye size [15].
For the actual screen, ey-Gal4,DVAP-P58S flies were crossed to mutants selected from publi-
cally available collections. As part of a large-scale gene disruption project, the Berkeley Dro-
sophila genome project (BDGP) generated thousands of mutations associated with stable
insertions of modified P-element transposons [31]. We focused on the screening of the EP and
the EPgy2 collections of genome-wide insertional mutations for dominant modifications of the
eye neurodegenerative phenotype associated with the ey-GAL4,DVAP-P58S strain. These col-
lections consist of UAS elements inserted in the promoters of endogenous genes and therefore
they can be used to overexpress the downstream gene if the UAS-binding transcription factor
GAL4 is co-expressed [32]. These collections were chosen for several reasons. Both collections
were generated by random insertions of P-elements throughout the fly genome thus represent-
ing a large, unbiased, genome-spanning set of mutant lines. Additionally, both the EP and the
EPgy2 collections comprise mutant lines in largely non-overlapping genes in which location
and orientation of P-element insertions were previously mapped making the identification of
the affected gene relatively straightforward.
A Network of Functional Interactions in ALS8
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We initially focused on the second and the third chromosome and selected 1,120 P-element
insertions that, based on the position and orientation of P-elements, are predicted to generate a
potential overexpression of the affected gene. For 16 genes for which no EP or EPgy2 insertion
lines with the potential of inducing overexpression were available, lines from the P{Mae-
UAS.6.11} collection were selected [33,34]. In addition, 47 EP and EPgy2 lines with P-elements
inserted in the opposite direction, and therefore with the potential of disrupting the affected
genes, were analyzed. As a result, a total of 1,183 lines were tested (S2 Fig).
While performing our screen, we realized that at 30°C, the temperature used to raise flies
for the detection of suppressors, the identification of enhancers was difficult as the enhancing
effect on the eye phenotype was too subtle. We noticed, however, that flies expressing
DVAP-P58S under the control of the ey-GAL4 line exhibit decreased viability possibly due to
the ectopic expression of the transgene in brain areas other than the eye. Although not carefully
quantified, at 30°C expression of DVAP-P58S in the eye results in organism lethality and this
effect is sensitive towards genetic modification as enhancers consistently lead to a decrease in
the number of eclosed flies. Subsequently, the enhancing effect on the DVAP-P58S eye neuro-
degenerative phenotype was confirmed by rearing flies at 28°C to make the DVAP-P58S eye
phenotype less severe. In this condition, scoring a putative enhancement of the eye phenotype
becomes much easier. At 28°C, DVAP-P58S flies also exhibit partial organism lethality with
80% of the expected number of flies, eclosing. The enhancement effect of modifiers was con-
firmed by assessing the increase in organism lethality at 28°C.
To eliminate false positives, all interacting insertions were retested two more times by an ex-
perimenter who was blind to the identity of the gene. Since we are interested in genes that pri-
marily modify the DVAP-P58S-dependent phenotype, lines exhibiting an eye phenotype when
driven by the ey-GAL4 line in the absence of the DVAP-P58S transgene were discarded. In
summary, only those lines that did not show a neurodegenerative phenotype in trans with ey-
GAL4 and for which results could be consistently repeated were designated as modifiers (S2
Fig).
Fig. 1A depicts light micrographs of representative eye phenotypes of one suppressor and
Fig. 1B shows scatter plots of actual surface areas for the same suppressor. Fig. 1C presents av-
erage surface areas of every suppressor resulting from a set of three independent experiments.
In Fig. 2, results of a representative enhancer (Fig. 2A,B) and data on the effect of the remaining
enhancers for viability and eye neurodegenerative phenotypes are presented (Fig. 2C). The
complete list of all suppressors is reported in S1 Table together with the percentage of modify-
ing activity of every modifier. S2 Table reports genes with an enhancing effect on both the eye
and organismal lethality phenotypes.
In summary, this primary screen identified 85 modifiers including 71 suppressors and 14
enhancers(S2 Fig). The 7% hit rate for genetic modifiers among the 1,183 tested strains is dou-
ble the number of 1–4% typically observed in similar genetic screens in Drosophila. This dem-
onstrates that the adopted approach was successful in identifying genes interacting with the
DVAP-P58S neurodegenerative phenotype. However, false positive are common in high-
throughput screens and therefore the effect of these modifiers was carefully and quantitatively
retested by using an independent allele and an additional assay.
Genetic validation of the identified modifiers
Insertions of P-elements within or close to a gene could make difficult to assign phenotypes to
specific genes with a high degree of confidence. However, if the ability of an EP or EPgy2 line
to genetically modify the ey-Gal4,DVAP-P58S phenotype is due to a disruption of the gene as-
sociated with the insertion, then other mutant alleles for that gene should also show a
A Network of Functional Interactions in ALS8
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modifying effect. On the basis of previous studies, we identified additional alleles for many
modifiers and tested their ability to modify the phenotype associated with the
DVAP-P58S construct.
For 62 out of the 85 modifiers, we were able to confirm the modifying effect of the specific
gene on the ey-Gal4,DVAP-P58S phenotype using independently generated alleles obtained
from other laboratories/stock Centers or by RNAi knock-down of the putative modifier(S3
Table, S2 Fig). More specifically, of the 71 suppressors 39 were confirmed by showing that an
RNAi line has an enhancement effect on the eye/lethality phenotypes. Similarly, 3 suppressor
lines were shown to be enhancers when loss-of-function alleles were tested to confirm their in-
teracting ability. Conversely, the suppressor effect of 5 genes was confirmed by UAS lines while
3 suppressors were confirmed by using an independent EP or EPgy2 line. For 3 suppressors,
the position and the orientation of the P-element suggest that the allele is likely to be a loss-of-
function and therefore the suppression effect was confirmed by using an RNAi line (for
HSPC300 and Hippo) or an independent loss-of-function allele (for Klarsicht). Finally, the sup-
pressive effect of the Syntaxin7/Avalanche gene was validated by using an antibody specific for
the corresponding protein that was shown to be abnormally distributed in ey-Gal4,DVAP-P58S
eye imaginal discs when compared to controls(S3 Fig). Of the 14 enhancers, 7 exhibited a
Fig 1. An overexpression screen for modifiers of the DVAP-P58S eye phenotype identified 71 suppressors. (A) Stereomicroscope images of external
eyes from control flies (ey-Gal4/+), flies expressing DVAP-P58S in the eye (ey,DVAP-P58S), flies expressingDVAP-P58S in the presence of an
heterozygous overexpression allele of Diap2 (ey,DVAP-P58S/Diap2G2326) and flies overexpressing Diap2 under the control of the ey-Gal4 driver (ey,
Diap2G2326). In controls, eye morphology is made up of a regular array of ommatidia, however expression of DVAP-P58S induces a reduction in eye size and
loss of ommatidial texture. Coexpression of DVAP-P58S and Diap2 leads to a highly significant suppression of the eye phenotype while overexpression of
the interacting gene on its own does not exhibit any phenotype. (B) Estimated eye surface area phenotype presented as scatter plots. Red horizontal lines
represent the average surface area of the indicated genotypes. (C) Quantification of eye surface areas of modifiers with a suppression activity. The average
eye surface area of each suppressor was measured, the area of the ey-GAL4,DVAP-P58S subtracted and the difference expressed as the percentage
change from the eye size reduction associated with the ey,DVAP-P58S tester line. The strongest suppressor is expected to have a suppression value of
100% and an eye size similar to that of the wild-type. Conversely, a weak suppressor has a suppression value close to zero and an eye size similar to that of
the ey,DVAP-P58S line. Results of three independent experiments for every suppressor are reported and red lines represent the average surface area for the
indicated suppressors. ***P<0.001. n = at least 15 flies per genotype. Scale bar: 50μm.
doi:10.1371/journal.pgen.1005107.g001
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suppressor effect with RNAi alleles and 2 were suppressors when loss-of-function mutations
were tested. In summary, by using genetic and immune-histochemical approaches, the effect of
63 out of 85 modifiers was confirmed(S2 Fig).
For the remaining 22 lines (17 suppressors and 5 enhancers), it was not possible to confirm
their effect by using RNAi lines. Although the relevance of these genes as potential modifiers of
the DVAP-P58S phenotype needed to be confirmed by using additional independent alleles,
for 21 of them the P-element insertion has been molecularly mapped and supposed to affect a
specific gene. It is therefore conceivable that in these cases, RNAi alleles generated only a weak
hypomorph so that the partial inactivation of the gene would not be sufficient to induce a visi-
ble effect. For the CG15630 suppressor line, however, the localization of the P-element inser-
tion made it difficult to assign the modifying effect to a specific gene and therefore, at the
moment, this gene remains a candidate modifier as it has been found to have an effect with
only one allele.
In conclusion, a total of 63 genes out 85 were confirmed to be modifiers of DVAP-P58S-in-
duced neurodegenerative phenotype in the adult eye since the modifying ability is caused by
changes in activity/expression of interacting genes and not by unrelated or genetic
background effects.
Fig 2. Enhancers of the DVAP-P58S eye phenotype. (A) Stereomicroscope images of adult fly eyes from controls (ey-Gal4/+), flies expressing
DVAP-P58S in the eye (ey,DVAP-P58S), flies expressing DVAP-P58S in the presence of an heterozygous overexpression allele of the representative
enhancerCaBP1EY12345 (ey,DVAP-P58S/CaBP1EY12345) and flies overexpressingCaBP1EY12345 under the control of the ey-Gal4 driver (ey/CaBP1EY12345).
(B) Estimated eye surface area phenotype presented as scatter plots. Red horizontal lines represent the average surface area of the indicated genotypes.
(C) Quantification of the eye surface areas and lethality of modifiers with an enhancing activity. See Materials and Methods for the calculation of the lethality
and the eye surface areas of every enhancer. Reported data result from at least three independent experiments. ***P<0.001. n = at least 15 flies per
genotype. Scale bar: 50μm.
doi:10.1371/journal.pgen.1005107.g002
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The modifying effect of DVAP-P58S interacting genes is extended to the
adult nervous system
Our main goal with the primary screen was to generate a short list of candidates that could
then be tested in a functional context that is more pertinent to the disease such as the motor
system. We confirmed and extended our analysis by testing whether the identified modifiers
also affect the DVAP-P58S-induced toxicity in neurons other than those of the adult eye and,
more specifically, whether they interact with DVAP-P58S to affect motor behavior. Pan-neural
expression of the DVAP-P58S construct under the control of the elav-Gal4 line does not result
in viable offspring at 30°C [15]. However, when flies of the same genotype are raised at 28°C,
about 70% of the expected offspring is viable and surviving flies exhibit a progressive decline in
locomotion ability. The motor performance of flies as a function of age was assessed and quan-
tified using a climbing assay. Control flies show no significant decrease in their motor perfor-
mance until later in life and, in particular, for the entire period during which the motor
performance was tested, about 80% of control flies were still able to climb (Fig. 3A,B,C, blue
lines). Conversely, flies expressing DVAP-P58S specifically in the nervous system using the
elav-Gal4 driver (elav-Gal4;DVAP-P58S), display progressive impairment of their motor per-
formance (Fig. 3A,B,C, red lines). We then analyzed the effect of every modifier on the climb-
ing phenotype associated with the expression of DVAP-P58S in neurons. As shown in Fig. 3A,
B for representative examples of two suppressor genes (black lines), climbing ability was dra-
matically improved compared to flies that expressed only DVAP-P58S. Conversely, Fig. 3C
(black line) reports an example of an enhancer where flies show a progressive worsening of the
phenotype over the same time period.
Data for all modifiers are reported in S4, S5, S6, S7 Fig. Suppressors were classified as strong
when they exhibited a consistent and robust suppression for at least three out of five time
points tested(S4 Fig). Suppressors with an intermediate effect displayed a significant change in
two time points out of five(S5 Fig). Finally, suppressors with a weak effect were those in which
performance was improved over the entire time period but differences were of high statistical
significance in only one time point or, mildly significant, over two time points (S6 Fig). Eight
genes identified as enhancers in the primary screen also exhibit a strong enhancing effect on
DVAP-P58S-induced motor dysfunction(S7 Fig). Out the 85 modifiers, 58 were found to have
a modifying effect on DVAP-P58S motor performance(S2 Fig).
To investigate whether the locomotion defects could be attributed to synaptic deficits, we
turned to the Neuromuscular Junction (NMJ) of third instar Drosophila larvae, a model gluta-
matergic synapse, the structural and functional properties of which have been extensively char-
acterized [35]. We examined the morphology of larval NMJs located on muscle 12/13 by
immunohistochemistry with antibodies against the presynaptic marker HRP. As previously re-
ported, elav-DVAP-P58S NMJs exhibit a reduction in the number of boutons and an increase
in their size when compared to controls [10,14]. Here we found that co-expression of either Ric
or Diap2, two potent suppressors of the DVAP-P58S-dependent eye and locomotion pheno-
types; also rescued the morphological defects of NMJs both in size and number of boutons
(Fig. 3D,E,F,G, I,J). Notably, expression of either Ric or Diap2 alone under the control of the
same elav-Gal4 driver does not result in any visible structural change at the synapse(S8 Fig). In
contrast to what was observed for Diap2 and Ric, co-expression of Smooth (Sm), a gene with an
enhancing effect on the DVAP-P58S-mediated eye and motor phenotypes, leads to a severe dis-
ruption of synaptic structural integrity at NMJs. Specifically, while in controls synaptic boutons
within a branch resemble a string of beads connected by a short neuritic process, the architec-
ture of NMJs co-expressing DVAP-P58S and Sm is profoundly altered and consists of a re-
duced number of irregularly shaped boutons which are frequently disconnected from the nerve
A Network of Functional Interactions in ALS8
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Fig 3. Effect of a subset of modifiers onmotor and synaptic structure abnormalities associated with the expression of DVAP-P58S in neurons. (A,
B) Representative analyses of two genetic modifiers showing suppression (Vamp7G7738 in A and AuxG6787 in B) and an enhancement (SmEY07191) in (C) of
motor defects associated with pan-neural expression of DVAP-P58S (elav;DVAP-P58S). (D-H) Representative confocal images of NMJs stained with anti-
HRP antibodies from elav-Gal4/+ control (D) and elav;DVAP-P58S larvae (E). (F,G) NMJs expressing DVAP-P58S and either one of two suppressor genes,
Diap2 (elav;DVAP-P58S/Diap2G2326 in F) or Ric (elav;DVAP-P58S/RicG2693 in G). (H) Representative images of NMJs stained with anti-HRP antibodies
expressing DVAP-P58S and one enhancer, Sm (elav;DVAP-P58S/SmEY07191). (I) Quantification of total number of boutons on muscle 12 and 13 of
abdominal segment 3 in elav-Gal4/+ control (275.3 ± 6.0, n = 8), elav;DVAP-P58S (156.4 ± 2.9, n = 8), elav;DVAP-P58S/Diap2G2326 (242.5 ± 3.3, n = 8) and
elav;DVAP-P58S/RicG2693 (244.4 ± 4.1, n = 8) NMJs. (J) Quantification of bouton size at muscle 12 (type I and type III boutons) of abdominal segment 3 in
elav-Gal4/+ control, elav;DVAP-P58S, elav;DVAP-P58S/Diap2G2326 and elav;DVAP-P58S/RicG2693 NMJs. The phenotypic decrease in number of boutons
and increase in their size in elav;DVAP-P58S is strongly suppressed by the co-expression of either Diap2G2326 or RicG2693 alleles (P< 0.001 in every case).
(K) Disruption frequency of NMJs in elav-Gal4/+ control (n = 94 NMJs/10 animals), elav;DVAP-P58S (n = 90 NMJs/10 animals), elav;DVAP-P58S/SmEY07191
(n = 87 NMJs/10 animals) and elav;SmEY07191 (n = 96 NMJs/10 animals) larvae. Quantification of disruption frequency is measured as the average
percentage of NMJs with severe structural abnormalities. Synaptic architecture is rarely altered in controls and in neurons of elav;SmEY07191 larvae. While
disruption is occasionally observed in larval neurons expressing DVAP-P58S compared to controls, this phenotype is significantly worsened by the co-
expression of the enhancer Sm (P< 0.001). Bar = 10 μm. Error bars denote SEM. ***P< 0.001.
doi:10.1371/journal.pgen.1005107.g003
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or axonal branches (Fig. 3D,H,K). Disruptions are very rare in controls and in elav,Sm synaptic
terminals and are occasionally found in in DVAP-P58S expressing NMJs but their frequency is
drastically increased by co-expression of DVAP-P58S and Sm (Fig. 3K). Finally, a small but sta-
tistically significant decrease in bouton number was observed when Smooth expression was in-
duced by the driver alone(S8F Fig). However, this defect is very mild compared to the
widespread disruption of synaptic structure due to the concomitant expression of DVAP-P58S
and Sm.
In summary, the strong correlation between modifying effects on locomotion behavior and
on synaptic morphology we reported for a subset of DVAP-P58S interacting genes, further
supports the functional relevance of the identified interactions.
While most modifiers were isolated as suppressors and confirmed to have a suppressive ef-
fect in the motor assay, DAP160 was isolated as a suppressor in the eye but exhibited an en-
hancing effect on the motor phenotype when broadly overexpressed in neurons. This apparent
contradiction suggests that perhaps a more complex interaction exists between DVAP-P58S on
one hand and the DAP160 gene on the other. Under these specific testing conditions, neuronal
expression of the three modifiers (rhomboid, Src42 and leak) exhibit an independent develop-
mental lethality thus impairing the testing of motor performance in adult flies. These genes
and the remaining modifiers that were not confirmed by the motor assay still represented
bona-fide interactors of DVAP-P58S phenotypes, although additional alleles or/and different
assay conditions will be required to assess their effects on DVAP-P58Smotor performance.
Importantly, these results show that our analysis identified 42 of the 85 tested as high-confi-
dence genetic modifiers(S2 Fig, S6 Table). Indeed these genes exhibit a modifying effect on
DVAP-P58S disease phenotypes by using more than one allele and two independent assays, the
eye neurodegenerative phenotype and the adult fly motor performance. In conclusion, a large
set of modifiers was found to affect both phenotypes, eye degeneration and locomotion ability,
in the same direction and there is indeed a strong correlation between the severity of the modi-
fying effect on eye neurodegeneration and that on locomotion impairment.
A reasonable test of success for any genetic screen would be the isolation of genes that we
would predict to interact with the DVAP protein on the basis of prior experiments. Not all the
Drosophila genes have been tagged with EP or EPgy2 insertions and we did not screen all the
available lines in the collections. Therefore the isolation of even a few such modifiers would
confirm that the screen has been successful. Indeed, we isolated several such genes. Most nota-
ble among them is rdgBβ. The gene rdgBβ is predicted to encode a phosphoinositide phospha-
tase that has not been extensively investigated hitherto. Previous studies suggest that rdgBβ
may have functions similar to those of the better characterized phosphodiesterase rdgB [36].
rdgB is the homologue of the human Nir2 gene that has been shown to interact with the
hVAPB protein to control Golgi transport in human cell lines [37]. In addition, we and others
have shown that a primary and conserved function of VAPB proteins is to control the levels of
phosphoinositides associated with cellular membranes [15,38,39]. Another gene isolated as a
strong modifier is leak. In C.elegans, the N-terminal MSP domain of VAPB is cleaved and se-
creted, serving as an extracellular ligand. The secreted MSP fragment binds LAR and Robo
family receptors on the muscle cell surface leading to alterations in actin organization and
changes in mitochondrial morphology and function [7,8]. Leak is the Drosophila homologue of
Robo2, a protein family controlling axonal pathfinding and tracheal system development [40].
In DVAPmutants, muscle phenotypes similar to those associated with the removal of the cor-
responding gene in C.elegans have been reported [7,8]. It is therefore possible that if leak is a
Robo2 receptor, the similarity in phenotypes between Drosophila and nematodes corresponds
to a similarity in molecular mechanisms underlying VAPB-mediated functions. In addition,
among the high-confidence DVAP-P58S interacting genes, our screen identified actin (S1
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Table) and mutations in profilin 1, which regulates actin polymerization, were recently linked
to ALS [41,42]. Our studies also uncover modifiers for which no involvement in VAPB func-
tion has been previously reported. Analysis of these genes could potentially illuminate novel
and so far unpredicted, functional processes involved in ALS8 pathogenesis.
Computational network analysis demonstrates that multiple processes
are involved in DVAP-P58S-mediated toxicity
Although we analyzed a large collection of genes, our screen was not saturating as less than
10% of the about 12,000 Drosophila genes were screened. Additionally, important modifiers
may have induced subtle changes in DVAP-P58S pathology, which would have been excluded
based on our strict criterion of robust suppression or enhancement of DVAP-P58S-associated
phenotypes. Therefore, we performed an extensive computational analysis of modifier genes in
order to extrapolate cellular processes, pathways and other genes that may have a relevant role
in DVAP-P58S-associated disease phenotypes. In the list of modifiers we also incorporated
DVAP as it has been shown that the wild-type protein binds to the ALS8-causing allele and is
sequestered into the aggregates. In addition, it appears that at least some of the interactions of
VAPB proteins are retained by the mutant allele [15,16]. It is therefore possible that the wild-
type version of the protein has an important role to play in the disease pathogenesis.
The 85 modifier genes were analyzed using the R/Bioconductor package ‘topGO’ which
uses a GO-graph de-correlation method to remove conditional dependence from the annotated
GO tree improving interpretation of results by removal of non-specific higher level terms and
allowing for multiple testing correction to control the false positive rate [43]. The predominant
processes enriched in the modifier list reflect broad effects on a variety of biological processes
reinforcing the concept of the pleiotropic nature of disease pathogenesis (Fig. 4A). Analysis of
the DrosophilaDVAP-P58S network with topGO identified endosomal regulation, lipid parti-
cle metabolism, vesicular trafficking and apoptosis as enriched functional categories (Fig. 4A).
Some of these biological processes, such as vesicular trafficking, have already been linked to
VAPB activity although their role in VAPB-mediated neurodegeneration has never been di-
rectly assessed [44,45]. Additionally, functional categories such as endocytosis and lipid parti-
cle metabolism represent biological processes that have not been previously associated with
VAPB activity (Fig. 4A). Based on a recent report showing that VAPB can function as an onco-
protein in humans [46], it is particularly intriguing that a number of modifiers fall within en-
riched functional categories related to apoptosis (Fig. 4A).
To further extend our analysis, we searched the GeneMania database [47] to determine
whether the genetic modifiers are interconnected through physical and genetic interactions as
well as colocalization studies. We found that 72 of the 85 genes are linked into a complex net-
work and, more importantly, 7 of the DVAP-P58S genetic modifiers (CG7324, Syx7, Ero1L,
Rab5, CG5118, rho and Spp) have previously been reported to be physical interactors of DVAP
[48] (Fig. 4B).
We also carried out a statistical analysis comparing our GeneMania derived network graph
to those produced by repeatedly sampling the GeneMania data set with 1000 randomised gene
lists of the same size. To summarise the topographical properties of the resulting groups of net-
work graphs we calculated the mean node-degree and mean node-betweeness, two properties
for which biological networks have been shown to have high values [49] and calculated Z-
scores for the comparison of both metrics between our graph and the distribution of random
gene graphs. We found significantly higher values for both mean node-degree (2.07x, Z = 4.67,
p = 3.05x10-6) and mean node-betweeness (2.86x, Z = 2.75, p = 0.006) consistent with our in-
terpretation that the network of DVAP-P58S modifiers is structurally very different from that
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Fig 4. Functional role and interactome analysis of genetic modifiers inDrosophila. (A) Drosophila functional categories overrepresented in the genetic
modifiers list. Enrichment significance is expressed as the-log10 transformed Benjamini-Yekutieli corrected p-value resulting from hypergeometric tests of
GO-term enrichment. In this process we de-correlate the modifier gene list annotated GO-tree to remove GO-term conditional dependence using the
weighted elimination method [43] so that we can performmultiple testing correction. (B) Drosophila interaction network for DVAP-P58S screen hits identifies
connections between most of them. 72 of the 85 genes that modify the DVAP-P58S phenotypes are annotated as black circles while network edges are
colored accordingly to the type of interaction. 13 of the 85 genes are excluded from the interactome that includes also DVAP (yellow).
doi:10.1371/journal.pgen.1005107.g004
A Network of Functional Interactions in ALS8
PLOSGenetics | DOI:10.1371/journal.pgen.1005107 March 31, 2015 12 / 32
produced from random gene lists and shares key topographical features commonly observed in
other known biological networks.
Together, these findings confirm and expand categories and pathways associated with
DVAP function and provide us with a perspective on the diverse molecular functions that can
modulate DVAP-induced pathogenesis in vivo.
Building the human interactome of DVAP-P58S genetic modifiers
Careful Drosophila to human homology mapping using a recently developed orthologue map-
ping tool (Drosophila RNAi Screening Center Integrative Orthologue Prediction Tool, DIOPT
at http://www.flyrnai.org/diopt) shows that of the 85 Drosophila genes at least 77 have human
orthologues (S4 Table). We decided to use DIOPT instead of any other specific software be-
cause it has the advantage of integrating the results of several orthologue searching tools based
on different algorithms [50]. This tool also includes algorithms identifying potential function-
ally related proteins in humans based on information derived from protein-protein interaction
networks. In searching for orthologues using this tool, we applied a filter that removed pre-
dicted human proteins with a DIOPT score less than 2 as this would mean that the identifica-
tion of this orthologue is supported by only one algorithm.
To search whether any of the identified modifiers are known to be associated with a disease
of the nervous system, we used a tool based on DIOPT named DIOPT-DIST (http://www.
flyrnai.org/diopt-dist). The DIOPT-DIST website links Drosophila genes to high-confidence
orthologues of disease genes extracting information from the Online Mendelian Inheritance in
Man data set and Genome-Wide Association Studies. We found that a considerable number of
human orthologues of genetic modifiers have been associated to neurological disorders includ-
ing neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases, multiple sclerosis
and spinocerebellar ataxias. Other genes were linked to human psychiatric disorders such as
schizophrenia, autism spectrum disorder and mental retardation(S5 Table). The recovery of
these genes suggests that the genetic network identified by our screen may overlap, perhaps sig-
nificantly, with the genetic networks associated with other human neurological disorders. If
this turns out to be true, the use of Drosophila to explore other neurological disease networks
via genetic screens would have the potential to identify common therapeutic targets that could
be tested in other disease models.
To study the DVAP-P58S genetic circuitry in the human context we generated a human
view of the genetic Drosophila interactome taking advantage of the manually curated source of
human molecular interactions from the Ingenuity Pathway Analysis (IPA database, Ingenuity
system at www.ingenuity.com). This database integrates human gene relationships derived
from a variety of experimental approaches including proteomic studies. Using the hVAPB pro-
teins and the 77 human genes homologous to the genetic modifiers identified in Drosophila, we
derived the human interaction network of hVAPB. The generated human interactome includes
hVAPB and 31 additional genes indicating that these proteins, which represent 40% of the
identified modifiers, are interconnected in the human IPA database (Fig. 5A). Importantly, we
found that all the genes included in the hVAPB interactome are also components of the Dro-
sophila genetic network further supporting the relevance of the fly modifiers for the elucidation
of the function of hVAPB and for ALS8 pathogenesis.
To further expand the hVAPB interactome, we identified proteins in the IPA database that
interact with hVAPB and incorporated them into the list of human orthologues of Drosophila
modifiers. In so doing, we established a new network of interconnected genes that include the
initial 31 modifiers and 12 additional ones (Fig. 5B). Our experimental data integrated with
our computational analysis support and reinforce the relevance of the Drosophilamodel in
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identifying the cellular processes and in dissecting the complex genetic network underlying
ALS8 pathogenesis in humans.
Computational and experimental analysis identifies endocytosis as a
process implicated in ALS8 pathogenesis
To perform a further functional characterization of a subset of modifiers, we focused on genes
that were present within both the Drosophilamodifier network and the expanded IPA human
network of hVAPB. A number of these genes include genes known to function in vesicular and
endocytic trafficking. Then we generated a sub-network including protein interactions relevant
to DVAP-P58S and proteins with Gene Ontology annotations related to vesicular trafficking
and/or endocytosis present in the GeneMania data base (Fig. 6A). A similar network was de-
fined for the human orthologues of these genes using IPA (Fig. 6B). Rab7 is among the genes
that are predicted to be part of both the fly and human network but that were not identified in
the screen. Rab7 is an endocytic marker of late endosomes that results from the maturation of
early endosomes labeled by Rab5. Rab5 is a potent modifier of DVAP-P58S phenotypes and we
showed that up-regulation of Rab5 functions as a potent suppressor(S1 Table).
To assess whether a similar effect could also be extended to Rab7, we crossed ey-Gal4,
DVAP-P58S flies with flies expressing either a wild-type or a constitutive active form of Rab7
and, in both cases, a strong suppression of the disease phenotypes was observed. (Fig. 6C,D,E).
While Rab5 and Rab7 provide important organelle identity markers for early and late endo-
somes respectively, Rab11 is instead the identity marker for recycling endosomes. As for Rab5
and Rab7, overexpression of a wild-type version of Rab11 suppresses the DVAP-P58S eye
neurodegenerative phenotype(S9 Fig). These results are particularly striking if we consider that
VAPB has been shown to bind to Rab7 and to be required for the proper spreading of late en-
dosomes throughout the cell [51,52].
To test the cellular distribution of endosomes, eye imaginal discs expressing the
DVAP-P58S transgene were stained with an antibody specific for Rab5. While in controls
Rab5-positive immuno-reactivity forms a granular pattern dispersed throughout the cell, Rab5
abnormally accumulates in cells expressing the DVAP-P58S transgene and partially overlap
with DVAP-P58S-induced aggregates (Fig. 7A,B). A similar effect was observed in neurons of
larval brains expressing DVAP-P58S under the control of the pan-neural driver elav-Gal4
(Fig. 7 C,D). These data suggest that inclusion of Rab5 proteins into aggregates and their inade-
quate delivery to the normal site of function may underlie DVAP-P58S-mediated neurodegen-
eration. Interestingly, we found that in eye imaginal discs simultaneously expressing Rab5 and
DVAP-P58S, Rab5 immunoreactivity exhibits, at least in part, a normal distribution(S10 Fig).
These data suggest that suppression of DVAP-P58S toxicity by overexpression of Rab5 proteins
occurs by replacement of those proteins that have been incapacitated by inclusion into
DVAP-P58S-induced aggregates. However, the elucidation of the mechanism whereby Rab5
protein expression confers protection against DVAP-P58S-associated neurodegeneration, re-
quires further investigation.
Fig 5. hVAPB human interactome. (A) IPA network between human orthologues of the Drosophila genetic modifiers that can be connected to each other
without intervening nodes. IPA analysis indicates that about 40% (28 genes out of 77) of the human orthologues of DVAP-P58S genetic modifiers are
connected in a network with other modifiers and hVAPB (red). In addition, three modifiers (STX7, VAMP7 and STX6) have interactions between them but not
with hVAPB interactome. Nearly 60% of the modifiers (46 genes) have no interactions that would connect them to hVAPB or other modifiers. Icons represent
the function of the node accordingly to the legend. (B) Extended human genetic network of hVAPB. Adding the direct and indirect interactors of hVAPB to the
network shown in (A) generated a novel and extended network. In this interactome, a total of 44 modifiers (green) are connected to hVAPB through 43
additional proteins from the IPA database (yellow). Direct interaction (solid line) indicates direct physical contact between two molecules, e.g. binding or
phosphorylation. Indirect interaction (dashed lines) indicates a functional interaction that does not require a direct contact between the two molecules (e.g.
signaling events).
doi:10.1371/journal.pgen.1005107.g005
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Collectively computational and experimental evidence provide proof that our data set is en-
riched for proteins such those involved in vesicular trafficking and endocytosis and that these
processes are important in DVAP function and patho-biology.
Fig 6. Computational and experimental analyses identify Rab7 as a modifier of the DVAP-P58S-mediated phenotypes. (A) Sub-network interactome
of Drosophilamodifiers (black circles) involved in endocytosis and vesicular trafficking. Predicted intervening nodes are depicted in grey. Color of edges
indicates the type of interaction according to the legend. (B) Interactome of human orthologues of Drosophilamodifiers involved in endocytic and vesicular
trafficking in green with intervening nodes predicted by the IPA system in yellow. Rab7 is indicated as predicted interacting gene in both networks. (C)
Stereomicroscope images of external eyes from control flies (ey-Gal4/+), flies expressing DVAP-P58S in the eye (ey,DVAP- P58S), flies expressing
DVAP-P58S in the presence of either a wild-type (Rab7wt) or constitutively active (Rab7Q67L) allele of Rab7. Quantification of the suppression effect on the
eye neurodegenerative phenotype (D) and motor performance (E) for flies of the indicated genotypes. Scale bar: 50μm.
doi:10.1371/journal.pgen.1005107.g006
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Rab5 accumulates abnormally in motor neurons of patients affected by
ALS
We next performed immunohistochemistry on human post-mortem spinal cord tissue to deter-
mine whether RAB5 is present in motor neurons and whether its localization is affected in
ALS. RAB5 is robustly expressed in spinal cord motor neurons and localizes to punctuate,
granular pattern distributed throughout the cellular cytoplasm (Fig. 8A). Conversely, RAB5 lo-
calization in autopsy tissues from two sporadic ALS cases reveals an abnormal accumulation
and clustering of RAB5 positive vesicles (Fig. 8B,C).
To analyze whether there was a co-localization between hVAPB and RAB5, we immunos-
tained post-mortem cervical sections of spinal cord from ALS patients and age-matched con-
trols. In controls, hVAPB was homogenously distributed throughout the neuronal cytoplasm
and showed a granular appearance consistent with the protein being localized in the endoplas-
mic reticulum (Fig. 8D). In agreement with what previously described [17,18], we also noticed
hVAPB expression was abundant in large motor neurons characterized by a prominent nucleus
and nucleolus while smaller cells were still positive for Rab5 immunoreactivity but essentially
devoid of hVAPB staining. In ALS tissues however, hVAPB staining was more conspicuous
than in controls and present as punctuate accumulations that partially overlap with redistrib-
uted Rab5 positive clusters (Fig. 8E,F). Previous studies have reported that in a few ALS cases
the expression levels of hVAPB protein is decreased. Reasons that could explain this apparent
Fig 7. Abnormal accumulation of Rab5 in larval eye imaginal discs and brains expressingDVAP-P58S. (A) control ey-Gal4/+ eye imaginal discs and
elav-Gal4/+ brains (C) immuno-stained with anti-DVAP and anti-Rab5 antibodies. Eye imaginal discs (ey,DVAP-P58S in B) and larval brains (elav;
DVAP-P58S in D) expressing the pathogenic allele were stained with the same antibodies. In controls, DVAP and Rab5 are homogenously distributed
throughout the cytoplasm but form large, overlapping aggregates in DVAP-P58S expressing cells. Scale bars: 10μm.
doi:10.1371/journal.pgen.1005107.g007
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discrepancy are not known but they could include differences in disease characteristics such as
disease duration and age of onset. Interestingly, we reported that in Drosophila expression of
DVAP wild-type protein is sufficient to trigger many hallmarks of the disease and that a recent-
ly identified ALS causing mutation in hVAPB mirrors the effects of DVAP wild-type overex-
pression and acts as an allele with increased wild-type activity [11]. These data indicate that in
humans as well as in fly models both gain and loss of function mechanisms may play an impor-
tant role in hVAPB-induced ALS.
Notably, a recent study has also reported an abnormal accumulation of RAB5, RAB7 and
RAB11 in post-mortem tissues of ALS patients [53]. Taken together, these data further support
Fig 8. RAB5 accumulates in the cytoplasm of spinal cord neurons of patients with ALS. (A-C) Immuno-
enzymatic detection of Rab5 in post-mortem tissues from ALS patients (B,C) and controls (A). RAB5 staining
shows punctuate and diffuse distribution of immunoreactivity throughout the cytoplasm, whereas RAB5
accumulates in cytoplasmic clusters of spinal cord neurons of patients affected by ALS. (D-F)
Immunofluorescence staining with anti-RAB5 and anti-hVAPB antibodies of spinal cord neurons from
controls (D) and ALS patients (E and F). In ALS tissues, RAB5 redistributes to form clusters that overlap with
hVAPB-positive immunoreactivity. Scale bar: 10μm.
doi:10.1371/journal.pgen.1005107.g008
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the notion that endocytic trafficking is important for ALS8 pathogenesis and that aberrant ac-
cumulation of endocytic markers can contribute to the human pathology.
Discussion
Amutation in the hVAPB gene was initially reported to be causative of a range of motor neu-
ron diseases including ALS8 [3]. The disease due to the P56S mutation in a conserved domain
of the protein is characterized by a high degree of heterogeneity in age of onset, severity and
clinical progression [3,54,55]. In a fly model of ALS8, severity of disease phenotypes has been
reported to strongly depend on the dosage/activity of the mutant allele suggesting that genetic
changes that either directly or indirectly affect DVAP function may be of therapeutic interest
[9,15]. Though VAPB proteins have been linked to a number of seemingly unrelated functions
[6,12,15,16,56], their interacting genes have not been systematically investigated nor has the
link between ALS8-causing mutations in the hVAPB gene and the specific loss of motor neu-
rons been uncovered. To systematically explore the genome for genes that are capable of modu-
lating hVAPB-mediated disease phenotypes in vivo, we took advantage of the ALS8 fly model
we recently developed [15]. This model offers the possibility of performing large-scale genetic
screens by using two phenotypic readouts: the neurodegenerative phenotype and the motor be-
havior analysis associated with expression of the disease-causing allele in the eye and the ner-
vous system, respectively [15, this study]. We identified numerous DVAP-P58S genetic
modifiers that fall within a variety of different functional categories suggesting a pleiotropic ge-
netic effect of ALS8 mutations in inducing neuronal dysfunction and death.
Overwhelming evidence supports a role of protein degradation deficits in neurodegenerative
diseases including ALS through disruption of either of the two major protein clearance path-
ways: the ubiquitin proteasome system and autophagy [57]. Autophagosomes accumulate in
the spinal cord of sporadic ALS patients [58] and a decrease in autophagic flux is present in
ALS mice and cell lines expressing mutant SOD1 [59]. Here we report that the autophagy-relat-
ed 7 (Atg7) protein, essential for autophagy, is a high-confidence suppressor of DVAP-P58S as
overexpression of Atg7 suppresses and its down-regulation enhances the DVAP-P58S-associat-
ed disease phenotypes(S6 Table). These data are consistent with a scenario in which the autop-
hagy process is down-regulated in DVAP-P58S expressing cells and are in agreement with
previous experiments reporting that mice lacking Atg5 and Atg7 in the nervous system exhibit
neurodegeneration [60,61].
The identification of ALS-causing mutations in genes affecting the ubiquitin-proteosome
system directly supports a role for this process in ALS pathogenesis. These genes include ubi-
quilin-2, p62/SQSTM1, optineurin, vasolin-containing protein, and charged multivesicular
body protein 2B ([2] and references therein). The ubiquitin-mediated protein degradation
pathway ensures that only proteins that are properly folded and assembled are transported to
their final destination. When mis/unfolded proteins are not degraded, an ER stress response is
induced, known as unfolded protein response (UPR). Previous studies have already implicated
VAPB proteins in protein homeostasis by showing that they can modulate the activities of the
IRE1 and ATF6 arms of the UPR [4,62].
Here, we report that several DVAP-P58S interacting genes including Cullin2, CG9153 and
CG4502, are involved in ubiquitin-mediated proteolysis. The ubiquitin-proteasome system is a
selective protein degradation pathway in which a substrate is first tagged with a chain of ubi-
quitin and the resulting modified protein is then recognized by the proteasome where its prote-
olysis takes place. The process of ubiquitination involves a three branched enzymatic cascade.
First, the chemically inert ubiquitin molecule is activated in an ATP-dependent reaction by
binding to an E1 activating enzyme. Second, ubiquitin is transferred to the active site of an E2
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ubiquitin conjugating enzyme. In the final step an E3 ubiquitin ligase functions to orchestrate
the transfer of ubiquitin to a substrate protein that needs to be tagged for degradation [63].
Cullins organize the largest class of RING-E3 ubiquitin ligases by functioning as molecular
scaffolds tethering a substrate target unit with the ring finger component that recruits the E2
ubiquitin conjugating enzyme [64]. Another type of E3 ubiquitin ligases is represented by the
Hect type. The single molecule HECT-type E3 ligases are characterized by a Homologous to
the E6-AP carboxyl terminus (HECT) domain that forms a thio-ester intermediate with ubi-
quitin as a pre-requisite for ubiquitin transfer to the substrate protein [65]. The CG9153
DVAP-P58S interacting gene encodes a putative HERC3 homologue in Drosophila. HERC3
contains a HECT domain and has been reported to associate with ubiquilin-2, an ALS causative
gene [66]. Finally, another modifier is the CG4502 that encodes a predicted E2 ubiquitin ligase.
Collectively these data provide further support to the notion that the ubiquitin-mediated pro-
tein clearance system represents a major component of ALS pathogenesis.
However, we were surprised to find that our list of modifiers is highly enriched for proteins
linked to lipid droplets (LDs), by either functional or proteomic studies. As an example, the
Acyl-CoA synthetase long-chain (Acsl) gene is a high-confidence modifier of DVAP-P58S phe-
notypes (S6 Table) and its vertebrate homologue ACSL3 has been implicated in LD biogenesis
[67]. LDs are ubiquitous organelles that collect, store and supply lipids [67]. The absence of
ACSL3 significantly reduces nucleation of emerging LDs, impairs accumulation of neutral lip-
ids and decreases size and numbers of mature LDs [67,68]. Here we show that overexpression
of Acsl ameliorates, while its down-regulation exacerbates, both neurodegeneration and motor
disabilities associated with neuronal expression of DVAP-P58S. These data indicate that Acsl
could be down-regulated in DVAP-P58S neurons and that impaired LD biogenesis may repre-
sent an important pathological aspect of VAPB-mediated ALS.
Importantly, we also found that loss of function mutations in the Drosophila gene Klarsicht
controlling motion and distribution of LDs [69] acts as a potent suppressor of DVAP-P58S
phenotypes (S6 Table). Aberrant movement of droplets can compromise their dispersion
throughout the cytoplasm. In C.elegans and mice, mutations in VAPB induce an aberrant clus-
tering of LDs in striated muscles that causes an energetic unbalance and a decrease in ATP pro-
duction following starvation [70]. Consistent with these data, large-scale proteomic studies
showed that DVAP is an LD-associated protein [71].
The functional role of LDs in the nervous system has been largely neglected, though recent
studies have reported that a number of LD proteins are abundantly expressed in the brain
[72,73] and some of them have been directly linked to motor neuron diseases. One such pro-
tein is seipin. Gain-of-function mutations of seipin cause motor neuron diseases known as Sil-
ver syndrome/spastic paraplegia 17 and distal hereditary motor neuropathy type V [74]. Seipin
is an ER resident protein that regulates LD morphology in yeast while in mammals is essential
for the induction of lipogenesis [75–77]. Mice expressing the seipin transgene carrying the dis-
ease-causing mutations, develop symptoms of motor neuron diseases along with an up-regula-
tion of ER stress markers and an induction of autophagy [78]. In addition, spartin/SPG20, a
protein mutated in the motor neuron disease known as the Troyer’s syndrome, is found on
LDs and is implicated in LD turnover [79]. Interestingly, it has been proposed that LDs may
play a protective role as they are large hydrophobic surfaces that sequester un-/mis-folded pro-
teins and prevent their accumulation in large inclusions [80]. This protective function may be
of general relevance also for motor neuron diseases for which the link with LD metabolism is
not directly evident. Indeed, SOD1 mouse models of ALS have been shown to benefit from a
fat rich diet that appears to attenuate disease symptoms [81]. Taken together, these data suggest
the intriguing possibility that maintaining normal levels of neutral lipid content may represent
a novel and promising therapeutic strategy in ALS.
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Here we show that computational and experimental analyses support a role for the endocy-
tic pathway in ALS8 pathogenesis. The endosomal system is necessary for regulating, sorting
and degrading proteins via autophagy or the ubiquitin proteasome-system. Rab-GTPases are
identity markers of endosomes and regulate endocytosis through interactions with vesicular
coat components, motor proteins and SNARE proteins. Incoming substances and receptors for
the regulation and fine-tuning of many cellular pathways are initially present on Rab5-contain-
ing early endosomes that undergo maturation to become Rab7-containing late endosomes
while Rab11 regulates recycling of endocytosed proteins via recycling endosomes [82]. Overex-
pression of several Rab-GTPases proteins including Rab5, Rab7 and Rab11, functions as potent
suppressor of DVAP-P58S associated phenotypes. Further supporting a link between hVAPB
and endocytosis, we identified as modifiers the SNARE proteins VAMP7 and Syntaxin 7,
which are required for late endosome-lysosome fusion events [83]. We also isolated as a modi-
fier the VPS35 gene, coding for a component of a retromer complex, which guides protein sort-
ing from the endosomal-lysosomal degradation pathway retrogradely to the Golgi network
[84]. Furthermore, we found an abnormal distribution of RAB5 into clusters overlapping with
hVAPB accumulations in ALS patients, suggesting hVAPB-mediated dysregulation of endoso-
mal trafficking in ALS pathogenesis. These data were confirmed by a recent report showing ab-
errant accumulation of RAB7- and RAB11-positive vesicles in post-mortem tissues of ALS
patients [53]. Interestingly, previous studies have shown that DVAP binds Rab7 and controls
intracellular positioning and distribution of late endosomes [51,52]. These data collectively in-
dicate that VAPB proteins have a broad and conserved function in facilitating endocytic traf-
ficking and that disruption of this process is a prominent cause of ALS pathogenesis.
Among the genes our genetic strategy identified as DVAP-P58S modifiers, there are several
members of the Ras signaling pathway, indicating that disruption of this pathway may play a
role in ALS pathogenesis. The Ras pathway, which enables cells to respond to external cues,
controls cell proliferation, differentiation and apoptosis. In metazoans, the protein Ras, Raf
and MEK act sequentially to activate ERK [85]. Remarkably, we report that DVAP-P58S-medi-
ated ALS phenotypes were sensitive to the dosage of a number of genes that function upstream
of Raf and downstream of Ras including connector enhancer of KSR (CNK), Src42 and 14-3-
3z. CNK functions as multivalent adaptor protein that cooperates with Ras and Src42 to induce
activation of Raf [86,87].
Interestingly, we show that Hippo (Hpo) may be up-regulated in neurons expressing the
DVAP-P58S transgene as reducing the genetic dosage of the tumor suppressor gene Hpo by
using two independently generated alleles is sufficient to suppress the effect of DVAP-P58S ex-
pression on the eye neurodegenerative phenotype(S6 Table). Additionally, the same genetic
manipulation fully rescued the locomotion defects associated with pan-neural expression of
the pathogenic transgene. In agreement with these data, overexpression of Hpo represses cell
proliferation and induces apoptosis [88] while the mammalian homologue MST1 is hyperacti-
vated in ALS patients and its down-regulation delays disease onset and extends survival in
SOD1 mice models for ALS [89].
It has been reported that Hpo promotes apoptosis by reducing the expression levels of a
number of downstream targets including the Drosophila inhibitor of apoptosis 1 (DIAP1) [90].
We have previously shown that DIAP1 is down-regulated in DVAP-P58S mutant background
and that up-regulation of DIAP1 mitigates DVAP-P58S neurodegeneration. These data pro-
vide further support to the hypothesis that in triggering neurodegeneration by apoptosis,
DVAP-P58S acts via the Hpo tumor suppressor pathway [15]. Recently, a high throughput
protein-protein interaction analysis looking for additional genetic members of the Hpo path-
way identified DVAP as a high-confidence member of the Hpo interactome [91]. This study
also implicated a fundamental role for the vesicular trafficking process in various aspects of the
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Hpo signaling and the importance of VAPB protein function in intracellular vesicular traffick-
ing has been well documented [44,45]. These data reinforce our genetic evidence supporting a
role for the tumour suppressor gene Hpo in ALS pathogenesis and provide a landscape of mo-
lecular interactions that can promote the formulation of additional mechanistic hypotheses to
be experimentally validated. Intriguingly, hVAPB can act as an oncoprotein as overexpression
of hVAPB in mammary epithelial cells induces an increase in cell proliferation and its expres-
sion levels are elevated in primary and metastatic tumor specimens [46].
Although further correspondence between the Drosophilamodel and the human condition
remains to be determined, the relationship between DVAP-P58 phenotypes and the Drosophila
modifiers, raises the possibility that pharmacological manipulation of these genes may assist in
developing treatments to ameliorate or prevent ALS-related abnormalities.
Note added in proof. While our manuscript was under revision, Liu and co-workers [92] re-
ported that reactive oxygen species due to mitochondrial dysfunction lead to LD accumulation,
which, in turn, promotes neurodegeneration both in Drosophila and mice. These findings are
in agreement with the data of our screen showing that one of the largest and most effective cat-
egories of DVAP-P58S modifiers is represented by genes involved in LD biogenesis and dy-
namics. Therefore these two works converge together in designating a role for LD dysfunction
in the aetiology of ALS and, possibly, other neurodegenerative diseases.
Materials and Methods
Screening methods and Drosophila husbandry
A stock carrying ey-GAL4 and UAS-DVAP-P58S on the second chromosome was established
by conventional recombination methods and used as a tester line for the screen. Individual EP
or EPgy2 lines were crossed to this line and the F1 progeny was tested for suppression or en-
hancement of the DVAP-P58S-derived small and rough eye phenotype. To prevent accidental
and progressive accumulation of extragenic modifiers of the DVAP-P58S phenotype, the ey-
Gal4,DVAP-P58S stock was maintained at 22°C or at 18°C degrees and in these conditions no
DVAP-P58S-induced eye phenotype was visible in the stock. Putative candidates isolated from
the screen were then maintained for the next round of analysis. To quantify the eye surface
area images were analyzed with ImageJ software (ImageJ software, National Institute of Health,
Bethesda, MD, USA). The phenotypic effect of doubling the dosage of the DVAP-P58S trans-
gene was studied in CyO+ progeny derived from the cross of ey-Gal4,DVAP-P58S/CyO flies
with flies carrying the DVAP-P58S transgene in homozygosity.
To test the effect of overexpressing candidate genes in the motor system, EP or EPgy2 indi-
vidual stocks were crossed to the tester line expressing the elav-GAL4 driver and the
DVAP-P58S transgene. For the genetic experiments in which the phenotypic analysis was per-
formed in the larval imaginal discs, the tester line was balanced over a “green balancer”. GFP
expression from the balancer chromosome was used to select larvae for dissection that do not
contain the balancer and on which the phenotypic analysis was carried out. Individual strains
from the EP and EPgy2 collections as well as from the P{Mae-UAS.6.11} collection were tested
for their ability to genetically modify the ey-Gal4-DVAP-P58S eye phenotype by mating 8 to 10
males of their strain to 10–15 females of the ey-GAL4,DVAP-P58S/CyO screening stock. After
2 days, adults were transferred to a fresh vial to create a duplicate cross and to maintain optimal
cultural density. For the same reason, adults were discarded from the duplicate vial after an ad-
ditional 2 days had passed. Embryos from both vials were raised at a temperature of 30°C in a
water bath to maximize the expression of the Gal4. For the analysis of the enhancing effect,
modifiers were first identified because, when compared to the tester line, they exhibit a reduc-
tion in the eye size and organism viability at 30°C. The potential enhancing effect of these lines
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was subsequently confirmed by quantifying the decrease in eye size and viability at 28°C. After
crossing females of the ey,DVAP-P58S/CyO-GFP line with wild-type Canton S males, the via-
bility of the tester line (Vtes) was calculated as a ratio between the number of CyO
+-GFP flies
(ey,DVAP-P58S/+) over the number of expected flies based on the Mendelian ratio. The viabili-
ty of the ey,DVAP-P58S in the presence of the enhancer line (Venh) was calculated in the same
way. The normalized lethality for every enhancer was expressed as (1-Venh/Vtes) x 100.
RNAi lines were acquired from the Vienna Drosophila RNAi Center while the entire overex-
pressor collection and a few TRIP RNAi lines were from the Bloomington Drosophila stock
Center.
Functional annotation and association network analyses
We performed gene set enrichment analysis (GSEA) on the modifier list by first de-correlating
annotated terms in the GO-graph using the weighted elimination method of [43] resulting in
conditionally independent GO-terms. We tested for term enrichment by hypergeometric test
and corrected for multiple testing by controlling the false discovery rate through application of
the Benjamini Yekutieli correction (α = 0.05). The Drosophila association network was ob-
tained by querying GeneMania with the modifier gene using all, but gene co-expression derived
interactions. In order to determine whether the network produced contained summary features
associated with real biological networks we compared the mean node-degree and mean node-
betweenness of the modifier network with those of GeneMania networks constructed from
1000 randomly selected gene lists of the same size. We calculated Z-scores comparing these
metrics between the modifier network and metric distributions from the random gene list de-
rived networks. Human orthologues were mapped using predictions made by the DIOPT sys-
tem. The modifier and the expanded hVAPB networks of the human orthologues were
generated through the use of IPA (Ingenuity Systems at www.ingenuity.com). All networks
were visualised using Cytoscape [93].
Climbing assay
Females of genotype elav-Gal4;DVAP-P58S were crossed to males of the mutant strains. Climb-
ing assays were performed on 10 age-matched adult female flies raised at 28°C as described in
[94]. The flies placed in a plastic vial were tapped to the bottom of the vial and the number of
flies above 8 cm line was counted after 15 seconds. A total of 10 trials were performed every
48 hours.
Immunohistochemistry on Drosophila larval tissues
Third instar larvae were dissected in cold 1x PBS and fixed at room temperature (RT) for
10 min in Bouin’s fixative (15 Picric Acid:5 Formaldehyde:1 Acetic Acid). Samples were
washed in 0.1% Triton-X100 in PBS (PBT) and blocked in PBT containing 10% NGS for
2 hours at RT before being incubated overnight at 4°C with primary antibodies. A rabbit Rab5
primary antibody (Abcam, ab18211) was used at a concentration of 1: 1000 and the same con-
centration was used for the DVAP primary antibody made in guinea pig. The anti-syntaxin
7 antibody was used at a concentration of 1:200. Primary antibodies were washed off with PBT
at RT for two hours by changing PBT every 15 minutes. Samples were incubated with second-
ary antibodies at RT for 2h and washed for 2 hours in PBT with changes of PBT every 15 min-
utes. Secondary antibodies were purchased from Jackson ImmunoResearch and used at a
concentration of 1:500. Stainings on NMJs were performed as previously described [15]. Tis-
sues were mounted in Vectashield Mounting Media (Vector Laboratories). Preparations were
imaged on a Zeiss Axiovert LSM510 confocal microscope.
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Immunohistochemistry on post-mortem human spinal cord tissues
Human tissue was obtained from the MRC Edinburgh Brain Bank with full ethical approval for
research studies by EoSRES (East of Scotland Research Ethics Service), Ref. No. 11/ES/0022.
For our analysis, we used 3 ALS cases and the same number of age-matched controls. The age
range of ALS cases was 55–63, with 2 females and 1 male case. Disease duration from diagnosis
to death ranged from 7 months to 22 months with an average of 13 months. All cases were spo-
radic and none of them showed the C9orf72 expansion. The age-matched controls died from
cardiac disease and after full neuro-pathological post-mortem examination, were considered to
have no neurological disease during life. Spinal cords from the cervical region were examined
in all cases.
Human spinal cord tissue fixed in 10% neutral-buffered formalin was processed into paraf-
fin. 7 μm sections were cut and de-paraffinized with xylene before being rehydrated through
graded ethanol solutions. Sections were pre-treated using heat-induced epitope retrieval with
Novocastra pH6 retrieval buffer in a decloaking chamber by heating to 125°C for 10sec, cooling
to 90°C before washing in running tap water. For immuno-enzymatic stainings, slides were
stained on a Leica Vision Biosystems Bond robot using the refine polymer detection kit (Leica)
as follows. Endogenous peroxidase was blocked with 3% hydrogen peroxide in TBST for
10 min. Sections were incubated with rabbit anti-RAB5 (1:250, Bethyl Laboratories) primary
antibody in 0.1% TBST for 2 hours at 25°C and then incubated with anti-rabbit HRP polymer
for 15 minutes at 25°C. Staining was visualized using 3,3’-diaminobenzidine as chromogen.
Tissue was finally subjected to haematoxylin staining, dehydrated through graded ethanol,
cleared in xylene and mounted in Pertex (Cellpath).
For immuno-fluorescence stainings, following dewaxing in xylene and rehydration in grad-
ed ethanols, sections were rinsed in water and then subjected to heat-induced epitope retrieval
by heating to 125°C in a decloaking chamber (Biomed) before passively cooling to 90°C in
Novocastra pH 6 retrieval buffer. Sections were washed in running tap water then placed on a
Leica Biosystems Bond X robot for dual tyramide staining as follows. Following blocking in 3%
H2O2 for 30 mins in Bond wash buffer and 30 mins in 20% normal goat serum, sections were
incubated with the RAB5 antibody at a 1:500 dilution for 60 mins. After two washes in Bond
buffer for 5 mins, sections were incubated with goat anti-rabbit peroxidase Fab fragments
(Abcam) for 30 mins. Sections were again washed twice for 5 mins in Bond buffer and incubat-
ed with Tyramide-Cy3 for 10 mins (PerkinElmer). After two additional washes in Bond buffer
for 5 mins, sections were subjected to heat-induced antigen retrieval for a further 10 mins
using Leica Bond ER1 solution on the robot. Following a wash in bond buffer and blocking in
3% H2O2 for 30 mins in Bond wash buffer and 30 mins in 20% normal goat serum, sections
were incubated with an anti-hVAPB antibody at 1:1000 dilution for 60 mins. Sections were
then incubated with goat anti-mouse peroxidase fab fragments (Abcam) for 30 mins and subse-
quently with Tyramide FITC for 10 mins (Perkin Elmer). Sections were mounted on slides
using permafluor (Thermo Scientific) and examined on a Zeiss Axiovert LSM510 confocal
microscope.
Statistical analysis
Statistical analysis was performed and graphs were generated using GraphPad 5.0. For experi-
ments with more than two samples, a one-way ANOVA test was applied. Tukey’s multiple
comparison test was then used as a post-hoc test when a significant difference was found in the
ANOVA test. For experiments with only two samples, a two-tailed unpaired Student’s t-test
was applied. For the climbing assay data, two-way ANOVA and Bonferroni as a post-hoc test
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were used to compare differences in motor performance between genotypes at different
time points.
Supporting Information
S1 Fig. DVAP-P58S induces eye degeneration in a dosage-dependent manner. (A-G) Ste-
reomicroscope images of external eyes from control flies (ey-Gal4/+) and flies expressing one
(ey,DVAP-P58S) or two (ey,DVAP-P58S/DVAP-P58S) copies of the DVAP-P58S transgene in
the eye at 25°C, 28°C and 30°C. (H) Estimated eye surface areas of the indicated genotypes pre-
sented as scatter plots. Red lines represent the average surface area of flies of the specified geno-
types raised at 25°C, blue lines for flies raised at 28°C and green lines for flies raised at 30°C. At
25°C a single copy of DVAP-P58S transgene induces a small but significant change in eye size,
while a severe reduction is observed with two copies of the same allele. At higher temperatures,
one copy of the transgene is sufficient to induce severe neurodegeneration in the eye, while ex-
pression of a double copy induces organism lethality. (I-M) Eye imaginal discs of control larvae
(ey-Gal4/+ in I), and larvae of the indicated genotypes incubated at the specified temperatures
were immuno-stained with anti-DVAP antibodies. In controls, DVAP immuno-reactivity has
a granular pattern distributed throughout the cytoplasm at any of the tested temperatures.
Only control eye imaginal discs from larvae incubated at 30°C are shown. A double dose of
DVAP-P58S at 25°C induces accumulation of aggregates similar to that caused by the expres-
sion of a single copy of the same transgene at higher temperatures. At 28°C, the accumulation
of aggregates is less drastic than at 30°C, while a few sporadic inclusions are present in eye
imaginal discs of larvae expressing only one copy of DVAP-P58S at 25°C. P<0.001. Scale
bars: 50μm for eye images and 10μm for eye imaginal disc stainings.
(TIF)
S2 Fig. Flow chart of the screen for genetic modifiers of DVAP-P58S-induced neurotoxicity
and motor impairment. The screen process is depicted including the results of each
screening step.
(TIF)
S3 Fig. Abnormal accumulation of Avalanche (Syntaxin7) in DVAP-P58S eye imaginal
discs. (A) Control (ey-Gal4/+) and (B) DVAP-P58S expressing eye imaginal discs (ey,
DVAP-P58S) immuno-stained with anti-DVAP and anti-Avalanche (Avl) antibodies. Both
proteins are homogenously distributed throughout the cytoplasm but Avl accumulates into ag-
gregates partially overlapping with DVAP-positive inclusions in DVAP-P58S expressing cells.
Scale bar: 10μm.
(TIF)
S4 Fig. Strong suppressors of the motor disability associated with DVAP-P58S expression
in neurons. Suppressors are classified as strong when exhibit a highly significant suppression
over at least three tested time points. Blue lines represent the control line (elav/+), red lines in-
dicate the elav;DVAP-P58S tester line and the black lines the elav;DVAP-P58S flies with the
modifying gene in trans-heterozygosity. P<0.001, P<0.01, P<0.05.
(TIF)
S5 Fig. Modifiers with an intermediate suppression effect on the motor disability associated
with DVAP-P58S expression in neurons. Suppressors are classified as intermediate when they
exhibit a significant effect over two time points. Blue lines represent the control line (elav/+),
red lines indicate the elav;DVAP-P58S tester line and the black lines the elav;DVAP-P58S flies
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with the modifying gene in trans-heterozygosity. P<0.001, P<0.01, P<0.05.
(TIF)
S6 Fig. Weak suppressors of the motor disability associated with DVAP-P58S expression in
neurons. Suppressors are classified as weak when they exhibit a significant suppression effect
only at one time point or a mild suppression effect over two time points. Blue lines represent
the control line (elav/+), red lines indicate the elav;DVAP-P58S tester line and the black lines
the elav;DVAP-P58S flies with the modifying gene in trans-heterozygosity. P<0.001,
P<0.01, P<0.05.
(TIF)
S7 Fig. Modifiers with an enhancing effect on the motor disability associated with
DVAP-P58S expression in neurons. Blue lines represent the control line (elav/+), red lines in-
dicate the elav;DVAP-P58S tester line and the black lines the elav;DVAP-P58S flies with the
modifying gene in trans-heterozygosity. P<0.001, P<0.01, P<0.05.
(TIF)
S8 Fig. Effect of neuronal expression of a subset of DVAP-P58S genetic modifiers on synap-
tic structure. (A-D) Representative confocal images of NMJs stained for HRP in elav-Gal4/+
control (A), in elav;Diap2G2326 (B), elav;RicG2693 (C) and in elav;SmEY07191 (D) larvae. (E)
Quantification of bouton size at muscle 12 (type I and type III boutons) of abdominal segment
3 in elav-Gal4/+ control, elav;Diap2G2326, elav;RicG2693 and elav;SmEY07191 NMJs. (F) Quantifi-
cation of total number of boutons on muscle 12 and 13 of abdominal segment 3 in elav-Gal4/+
controls (275.3 ± 6.0, n = 8), elav;Diap2G2326 (259.3 ± 4.8, n = 8), elav;RicG2693 (254.1 ± 4.8,
n = 8) and elav;SmEY07191 (235.3 ± 3.7, n = 8) NMJs. Expression of Ric and Sm induces a small
but statistically significant decrease in bouton number compared to controls. However, co-ex-
pression of Ric and DVAP-P58S induces a significant amelioration of DVAP-P58S synaptic
phenotype while expression of Sm exacerbates the DVAP-P58S phenotype by leading to a se-
vere disruption of the synaptic structural integrity. Scale bar: 10μm. Error bars denote SEM.
 P< 0.001,  P< 0.05, n.s. P> 0.05.
(TIF)
S9 Fig. Overexpression of Rab11 suppresses the neurodegenerative phenotype associated
with DVAP-P58S expression. Stereomicroscope images (A) and quantification of surface
areas (B) of flies of the indicated genotypes. P<0.001. Scale bar: 50μm.
(TIF)
S10 Fig. Expression of Rab5 in DVAP-P58S eye imaginal discs induces, at least in part, a
normal Rab5 distribution. (A) Control ey-Gal4/+ eye imaginal discs and (B) imaginal discs
expressing either DVAP-P58S alone (ey,DVAP-P58S) or (C) DVAP-P58S together with Rab5
(ey,DVAP-P58S/Rab5EY10619) were stained with antibodies as indicated. While Rab5 is localized
to small punctuate structures in controls, it accumulates and overlaps with DVAP-positive ag-
gregates in DVAP-P58S eye imaginal discs. In discs in which DVAP-P58S and Rab5 are simul-
taneously co-expressed, Rab5 localization appears to be, at least in part, normal. Scale bars:
10μm.
(TIF)
S1 Table. List of suppressors recovered from the functional genetic screen. Drosophila full
names and gene symbols are listed along with the allele used for each gene, its stock identifica-
tion number and the symbol of the relative human orthologue. The degree of modifying activi-
ty is also reported for every suppressor. Known molecular activities associated with
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suppressors were identified using the PANTHER classification system (www.pantherdb.org).
(DOCX)
S2 Table. List of genes with an enhancing activity. Drosophila full names and gene symbols
together with the allele used for each specific gene, its stock identification number and the sym-
bol of the corresponding human orthologue are reported. The scored phenotypes (eye, lethali-
ty) and the degree of modifying activity for every interacting gene is indicated. Known
molecular activities for each enhancer were identified according to the PANTHER classifica-
tion system (www.pantherdb.org).
(DOCX)
S3 Table. Validation of the modifying activity of identified hits. Drosophila full names and
gene symbols are reported together with the name of the new allele used, the validated pheno-
types (eye, lethality or both) and the degree of suppression/enhancement effect. The effect of
the identified modifiers was confirmed using an independent allele. The majority were con-
firmed by using an RNAi line from the VDRC stock Center and these alleles are indicated with
a “v” preceding their line number. A few modifiers were confirmed by using a TRIP RNAi line
and are indicated with a “t” preceding the ID stock number. Some genes were validated using a
specific UAS line or an independent EP or EPgy2 overexpressor line. A few genes were con-
firmed using a loss-of-function allele while syntaxin 7 was confirmed using a specific antibody
(S3 Fig). A list of unconfirmed modifiers is reported possibly due to an insufficient knockdown
of the gene targeted by the selected RNAi line.
(DOCX)
S4 Table. Seventy seven of the eight five modifiers have a human orthologue. Drosophila full
names and gene symbols are reported for every genetic hit along with the gene symbols, full
names and gene ID of the corresponding human orthologue. The DIOPT system used for ho-
mology searches relies on a combination of 10 different algorithms. Human orthologues identi-
fied by only one algorithm (DIOPT score< 2) are not reported.
(DOCX)
S5 Table. Human orthologues of DVAP-P58Smodifiers causing neurological disorders.
Symbols of the Drosophila gene and its human orthologue are reported along with the name of
the disease, the MIM number and the source of information (OMIM or GWAS).
(DOCX)
S6 Table. Classification of DVAP-P58S modifiers according to validation tests and pheno-
typic readouts.
(DOCX)
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